Elsilimomab

• Description :

  Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) [1][2][3].

• Product Name Alternative :

  B-E8; Anti-IL-6 MAB B-E8

• UNSPSC :

  12352203

• Target :

  Interleukin Related

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/elsilimomab.html

• Purity :

  98.44

• Solubility :

  H2O

• Smiles :

  [Elsilimomab]

• Molecular Weight :

  (145.96 kDa)

• References & Citations :

  [1]Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22 (7) :1254-1265.|[2]Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102 (2) :381-390.|[3]Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411 (4) :791-807.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported

• Isoform :

  IL-6

• CAS Number :

  [468715-71-1]